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Many diseases of the nervous system are accompanied by alterations in synaptic functions. Synaptic
plasticity mediated by the endogenous cannabinoid system involves the activation of the cannabinoid
receptor 1 (CB1R). The principles of CB1R signaling must be understood in detail for its therapeutic
exploration. We detected the Src homology 3-domain growth factor receptor-bound 2-like (endophilin)
interacting protein 1 (SGIP1) as a novel CB1R partner. SGIP1 is functionally linked to clathrin-mediated
endocytosis and its overexpression in animals leads to an energy regulation imbalance resulting in
obesity. We report that SGIP1 prevents the endocytosis of activated CB1R and that it alters signaling via
the CB1R in a biased manner. CB1R mediated G-protein activation is selectively inﬂuenced by SGIP1, b-
arrestin associated signaling is changed profoundly, most likely as a consequence of the prevention of the
receptor's internalization elicited by SGIP1.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Signaling via seven transmembrane receptors, also called G-
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Ltd. This is an open access article umechanisms. These include post-translational modiﬁcations, the
recruitment of b-arrestins, endocytosis and interactions with reg-
ulatory and scaffold proteins.
Cannabinoid receptor 1 (CB1R) is activated by endogenous
cannabinoids (e.g. anandamide or 2-arachidonylglycerol), as well as
by a range of exogenous ligands including -()-trans-D9-
tetrahydrocannabinol (THC), the psychoactive compound found in
the plant Cannabis Sativa. Localized principally presynaptically
CB1R is abundant in many central nervous system (CNS) structures
including the hypothalamus, hippocampus, nucleus accumbens,
prefrontal cortex, cerebellum and the emetic centers in the brain-
stem. Activation of this receptor leads to attenuation of either
inhibitory or excitatory synaptic transmission (Kano et al., 2009).
Like other GPCRs, CB1R regulates a diverse range of intracellular
signaling pathways. The array of signals that are modiﬁed depends
on the intrinsic properties of the ligands, the functional state of the
receptors (secondary modiﬁcations, e.g. phosphorylation, ubiq-
uitination etc.) and the intracellular environment (especially mo-
lecular components of signaling pathways and scaffold, together
with regulatory proteins that are in close proximity). The G-protein
signaling of CB1R leads to inhibition of adenylyl cyclase, negative
modulation of various calcium channels, and activation of inwardly
rectifying potassium channels. The extracellular signal-regulatednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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independent manner, in an agonist-speciﬁc way (Laprairie et al.,
2014). Intracellular portions of the receptor play a crucial role in
desensitization and internalization of the CB1R, a process related to
the development of tolerance to agonists. Signaling of CB1R triggers
activation of GPCR kinases or protein kinase C, resulting in receptor
desensitization. Phosphorylation of two serine residues (S426,
S430) within the C-terminus elicits receptor interaction with b-
arrestins (Garcia et al., 1998; Morgan et al., 2014; Straiker et al.,
2012). In heterologous cell systems, b-arrestin recruitment trig-
gers a cascade of events resulting in the clathrin-mediated endo-
cytosis (CME) of receptors (Hsieh et al., 1999). In addition to
heterologous expression systems, rapid CB1R internalization is
characteristic for the pool of CB1R located in the neuronal soma
(Simon et al., 2013), while the CB1Rs in axons, and especially at
synapses, are resistant to internalization (Leterrier et al., 2006;
Mikasova et al., 2008; Stadel et al., 2011). The molecular mecha-
nisms underlying these differences in endocytosis of the activated
CB1Rs are unknown.
The carboxyl termini of GPCRs mediate multiple protein-protein
interactions. Cannabinoid receptor-interacting protein 1a (CRIP1a)
decreases CB1R Gai/o mediated signaling. In addition, ERK1/2
signaling is attenuated in the presence of CRIP1a (Blume et al.,
2015; Niehaus et al., 2007; Smith et al., 2015). To investigate the
role of intracellular proteins affecting CB1R trafﬁcking and
signaling, we employed the yeast two-hybrid system (Y2H) to
identify proteins that interact with the C-terminus of CB1R.
We identiﬁed the Src homology 3-domain growth factor
receptor-bound 2-like (endophilin) interacting protein 1 (SGIP1) as
a novel molecule associated with CB1R. We describe that SGIP1
interferes with CB1R internalization and inﬂuences its signaling in
a biased manner, and may explain its dual internalization behavior
in distinct neuronal compartments.2. Methods
All chemicals were obtained from Sigma-Aldrich (Czech Re-
public), unless speciﬁed. All reagents for cell culture and trans-
fection were purchased from Thermo Fisher Scientiﬁc Inc. (USA).
WIN 55,212-2 mesylate (WIN) was obtained from Tocris R&D (USA)
and 2-Arachidonoylglycerol (2-AG) and AM-281 from Cayman
Chemicals (USA). Prior to making speciﬁc dilutions, a 10 mM stock
was prepared in dimethyl sulfoxide (DMSO). The vehicle controls
always contained appropriately diluted DMSO.
For primary neuronal cultures preparations, animals were
treated in accordance to applicable local laws and were carried out
in accordance with EU regulations. All efforts were made to mini-
mize animal suffering, reduce the number of animals used and
utilize alternatives to in vivo techniques, if available.2.1. Expression vectors
The cDNA coding for mouse SGIP1 was purchased from True-
Clones (Origene Technologies, Inc., USA), plasmids coding CB1R and
CB1R N-terminal-GST fusion construct were kindly provided by
Ken Mackie from Indiana University, Bloomington, Indiana, USA.
Both full-length protein sequences were ampliﬁed using degen-
erate oligonucleotides for PCR, and inserted into pRK5 vector or
pRK5with a Flag-tag or YFP-tag. SNAP-tagged CB1Rwas generously
provided by CisBio Bioassays (France). Expression vectors for Gqi9,
b-arrestin1-Rluc, b-arrestin2-Rluc, Gai1-Rluc8, GaOA-Rluc8, Gb-
Flag, Gg-VENUS and empty vector pRK6 have been described pre-
viously (Brule et al., 2014).2.2. Yeast two-hybrid assay
All reagents for the yeast two-hybrid (Y2H) assay, yeast strains,
plasmids and DNA library were purchased from Clontech Labora-
tories (Clontech Laboratories Inc., France) and handled according to
the manufacturer's instructions. Identiﬁcation of CB1R C-terminal
(amino acids 420e473) interaction partners was performed with
the MATCHMAKER Two-Hybrid System 3 according to the manu-
facturer's instructions. The CB1R bait was then cloned by PCR into
the pGADT7 vector, transformed into the Saccharomyces cerevisiae
strain AH109 and mated with pre-transformed Matchmaker rat
forebrain Saccharomyces cerevisiae strain Y187 cDNA library. Mated
cells were selected on SD media plates lacking Ade, His, Leu, Trp
and containing X-Gal. Plasmid DNAwas isolated from blue colonies
and sequenced. For further interaction analyses, the carboxyl ter-
minal of CB1R was mutated by site-directed mutagenesis. To
conﬁrm the originally identiﬁed interaction, we co-transformed
both prey and bait vectors into the AH109 yeast strain by heat
shock and grew them on SD/-Ade/-His/-Leu/-Trp/X-a-Gal media.
This method was also used to test further interaction with the
mutated CB1R C-terminus.
2.3. Cell culture and transfections
Human Embryonic Kidney 293 (HEK293) cells were cultured in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) containing glucose
and L-glutamine supplemented with 10% fetal bovine serum (FBS)
at 37 C, 5% CO2 and 95% humidity. Transient transfections were
carried out either on 12 mm cover slips (Glaswarenfabrik Karl
Hecht GMbH&Co KG, Germany) in 24 well plates (TPP, Switzerland)
coated with poly-L-lysine or in 96 well plates (Greiner BioOne, UK)
coated with poly-L-ornithine, using Lipofectamine™ 2000 accord-
ing to the manufacturer's instructions. The total amount of DNA
was kept at 800 ng/well (24 well) or 200 ng/well (96 well). Mock
cells were transfected with an empty vector. Experiments were
performed 24 h after transfection.
Rat embryonic cortical neurons E18 were isolated from Wistar
rat brains and cultured as described previously (Brewer et al., 1993).
Cell isolation was performed in Hank's Balanced Salt Solution
(HBSS) supplemented with 10 mM HEPES (pH 7.0) and 0.25%
Trypsin using Pasteur pipettes for tissue disruption. Approximately
750 cells/mm2 were cultured on poly-L-lysine coated 18 mm cover
slips in Neurobasal medium supplemented with B27, 0.5 mM L-
glutamine and antibiotic mix.
2.4. Bioluminescence resonance energy transfer assay
To study the SGIP1-CB1R association, cells were transfected
with SGIP1 N-terminally fused with Rluc (SGIP1-Rluc), and CB1R C-
terminally fused with YFP (CB1R-YFP), while b-arrestin1 tagged N-
terminally with YFP (b-arrestin1-YFP) was used as a negative con-
trol. For G-protein activation measurements, cells were transfected
with tagged Ga, b, g subunits together with CB1R-SNAP and Flag-
SGIP1 or pRK6 (1:1:1:1:2). For b-arrestin recruitment experi-
ments, cells were transfected with CB1R-YFP, b-arrestin1 or 2-Rluc
and Flag-SGIP, DynK44A or pRK6, respectively (2:1:2). Transfected
cells were washed twice with 150 ml PBS and coelentherazine h
(Molecular Probes, USA) was added at a ﬁnal concentration of 5 mM.
Cells were stimulated with agonist or vehicle DMSO for the indi-
cated time, or a fewminutes after coelentherazine h addition in the
G-protein activation experiment. Readings were performed
immediately on a Mithras LB940 plate reader (Berthold Bio-
technologies, Germany). The data are presented as speciﬁc BRET
signal (net mBRET) calculated as the emission ratio 530 ± 25 nm/
485 ± 20 nm  1000 from cells transfected with both donor and
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fected with an empty vector instead of the acceptor fusion protein.
Data analyses were performed using Prism6 (GraphPad software,
USA). For SGIP1-CB1R association YFP signal was measured in black
plates at 535 nm ± 25 nm after excitation at 485 nm. Signal from
cells transfected with pRK6 instead of the YFP fused constructs was
subtracted and the speciﬁc YFP signal obtained was divided by the
Rluc signal measured at 485 ± 20 nm.
2.5. Antibody production and characterization
We generated and characterized a novel serum in guinea pig
against the synthetic peptide linked to thyroglobulin against the N-
terminal SGIP1 epitope MMEGLKKRTRKAFGIRKKEKDTDSTGSC-
COOH in the same manner as described previously (Techlovska
et al., 2014). Protein samples for SDS-PAGE corresponding to
50 mg of cell lysate were separated on polyacrylamide Tris-glycine
gel (10%). Separated proteins were transferred onto nitrocellulose
membranes (Pall Corporation, USA). Membranes were blocked in
5% blotting-grade powdered milk (Carl Roth, Germany) and labeled
with the following antibodies: primary anti-SGIP1 1:1000 and
secondary goat anti-guinea pig IgG-HRP antibody (Santa Cruz
Biotechnology, USA) 1:5000; primary mouse anti-Flag M2 antibody
(Sigma-Aldrich, Czech Republic) 1:1000 and secondary goat anti-
mouse IgG-HRP antibody (Promega, USA) 1:10 000; primary rab-
bit anti-actin antibody (Sigma-Aldrich, Czech Republic) 1:10 000
and secondary goat anti-rabbit IgG-HRP antibody (Promega, USA)
1:10 000. Samples were visualized using the SuperSignal West
FEMTO chemiluminescent substrate system (Thermo Fisher Sci-
entiﬁc, USA) and detected on the LAS-300 system (Fujiﬁlm, USA).
In-house developed a-CB1R05 rabbit antibodies recognizing the
N-terminus epitope fused to GST (a.a. residues 1e66) were used for
co-immunoprecipitation studies. These a-CB1R05 antibodies were
characterized for their speciﬁcity on immunoblots from both CB1R
transfected HEK 293 cells and mock cells.
2.6. Detergent solubilization and co-immunoprecipitation
Previously described procedures were used with minor adjust-
ments (Techlovska et al., 2014). Brieﬂy, 20 ml of Protein A/G beads
(Thermo Scientiﬁc) slurry was incubated with 1 ml a-CB1R05 sera
overnight. The following day, mouse brain tissue was homogenized
at 5 mg/ml total protein in buffer A (100 mM NaCl, 20 mM Tris; pH
7.4; with protease inhibitor cocktail tablet (Roche, USA)). In addi-
tion, 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS) was added to the mix to a ﬁnal con-
centration of 1%, incubated at 37 C for 1 h and then centrifuged at
100,000 g for 1 hour. The supernatant was diluted (1:10) with
buffer A containing 0.1% Triton X-100. Next, 1 ml of the diluted
sample was mixed with the A/G beads bound with antibodies and
rotated at 4 C for 3e4 hours. The beads with bound fractions were
then washed 3 times in buffer A containing 0.1% Triton X-100. The
samples were then incubated with 50 ml of SDS-PAGE treatment
buffer (0.25 M Tris-Cl, 8% SDS, 20% glycerol, 0.02% bromophenol
blue, 0.04 M DTT, pH 6.8) for 10 minutes at 70 C. Finally, 10 ml of
each sample was resolved on SDS-PAGE, blotted onto nitrocellulose
membrane and the immunoprecipitate/co-immunoprecipitate was
visualized using corresponding antibodies.
2.7. Immunoﬂuorescence labeling
Primary cortical neurons 9th day in vitro or transiently trans-
fected HEK293 cells were ﬁxed for 13 min in fresh 3% para-
formaldehyde (Electron Microscopy Sciences, USA) diluted in
Phosphate Buffered Saline (PBS). Fixed cells were permeabilized for10 min in mild permeabilization buffer containing 0.025% Triton X-
100, 0.05% Tween 20 and 1% bovine serum albumin (BSA) in PBS
(pH 7.4). Primary antibodies were diluted in PBS containing 0.01 M
Tris and 1% BSA (pH 7.4). Homemade afﬁnity puriﬁed polyclonal
antibodies: guinea pig anti-SGIP1 1:500, rabbit anti-Bassoon
(KK06/A63) 1:2000 (kindly provided by Eckart D. Gundelﬁnger
and Anna Fejtova from Leibniz Institute for Neurobiology, Ger-
many) and commercial polyclonal rabbit anti-CB1R 1:200 (Alo-
mone Labs, Israel), mouse monoclonal anti-MAP2 1:2000, mouse
monoclonal anti-Tau1 (Millipore, Czech Republic) 1:500 and anti-
Flag M2 antibody (Sigma Aldrich, Czech Republic) 1:500 were
used for tandem staining of endogenous proteins as indicated. The
secondary antibodies Alexa Fluor® 488 goat anti-rabbit IgG (H þ L;
Life Technologies, USA) 1:1000, Cy™3-conjugated Afﬁni-Pure
donkey anti-guinea pig IgG (H þ L; Jackson ImmunoResearch, UK)
1:300 and C™5-conjugated Afﬁni-Pure goat anti-mouse IgG (Hþ L;
Millipore, Czech Republic) 1:300 were used according to manu-
facturer recommendations.
The modiﬁed live-cell immunoﬂuorescence labeling protocol
was used for immunoﬂuorescence CB1R internalization assay in
HEK293 cells (Lavezzari et al., 2004). Next, the cells were tran-
siently transfected with CB1R and pRK6 (1:1) or CB1R and Flag-
SGIP1 (1:1) constructs (total cDNA used was 800 ng/well in
24well plates). After 24 h, the cells were incubatedwith rabbit anti-
CB1R antibody (1:400) in complete cell culture medium at 37 C for
2 h and then stimulated with 0.5 mM WIN 55,212-2 diluted in
complete culture medium for 30 minutes at 37 C before the
standard ﬁxation step (3% paraformaldehyde, 13 min, room tem-
perature). Tandem staining with secondary antibodies was per-
formed at room temperature with a saturated concentration of
anti-rabbit antibodies in PBS for 45 minutes. First, Alexa Fluor®
488 goat anti-rabbit IgG (H þ L; Life Technologies, USA) diluted
1:250 was employed, followed by the standard permeabilization
step (see above) and application of Alexa Fluor® 633 goat anti-
rabbit IgG (H þ L; Life Technologies, USA) 1:250.
2.8. Image acquisition, processing and analysis
Microscope slides of ﬁxed and labeled neurons were scanned on
an inverted ﬂuorescent microscope Leica DMI6000 with confocal
extension Leica TCS SP5 AOBS TANDEM confocal superfast scanner;
objective 63  1.4 oil (Leica Microsystems, Germany). Slides with
HEK293 cells were scanned on an inverted ﬂuorescencemicroscope
Delta Vision Olympus IX-71; objective 60/1.42 Plan APO N oil
(Olympus, Japan). Deconvolution was performed using Huygens
Software (Scientiﬁc Volume Imaging B.V., the Netherlands). The
point spread function and chromatic aberration of the objective
were determined by measurement of 100 nm beads. Further image
analysis was performed using ImageJ (NIH, USA).
Co-localization analysis in neuronal cultures was performed
from ﬁve regions of interest (ROIs) in each set of images by evalu-
ating the co-localization of signals in different image channels ac-
quired in these areas. We applied Pearson's (PC) andMander's (MC)
correlation coefﬁcients mean values (xPC and xMC) (Bolte and
Cordelieres, 2006). The PC value ranges from 1 to 1, with 1 indi-
cating for complete positive correlation, 1 for negative correlation
and zero for no correlation. As PC values are dependent on noise,
variations in ﬂuorescence intensities and the type of ﬂuorescence
pattern, the MC coefﬁcient was also applied to correlate co-
localization of the channels based on an overlapping pixel
pattern. This coefﬁcient uses the average intensity values of two
channels and values range from 0 to 1 proportionally correspond-
ing to overlap (Lavezzari et al., 2004). As coefﬁcients are sensitive to
background levels, automatic Costes' approach was applied to
separate image signal from the background (Costes et al., 2004).
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B, corresponding to the cell surface CB1R labeled with Alexa 488
(S), the internalized CB1R labeled with Alexa 633 (I) and the
background of images outside the cells (B) respectively, were
measured using ImageJ. The background ﬂuorescence B was sub-
tracted from the S and I values, which, once multiplied by the
respective areas, yielded the S* and I* total speciﬁc ﬂuorescence
(Leterrier et al., 2006). The ﬂuorescence internalization ratio (FIR)
was calculated as I*/S*. For each condition, eight cells from three
independent experiments were used. Data were statistically
analyzed using Prism6 (GraphPad software, USA).
2.9. Internalization assay
Levels of receptor internalization were determined by Forster's
resonance energy transfer assay (FRET) as described previously
(Maurel et al., 2008). The cells transfected with SNAP-CB1R and
Flag-SGIP1 or DynK44A or pRK6 (1:2) were labeled with 100 nm
SNAP-Lumi4Tb in Tag-lite labeling medium (CisBio bioassays,
France). The level of receptor internalization was measured after 4
washes in Tag-lite labeling medium containing 24 mM ﬂuorescein
(Sigma Aldrich, Czech Republic) after cell stimulation with 2.5 mM
WIN or DMSO using an Inﬁnite F500 microplate reader (Tecan
Group Ltd., Switzerland). Both donor emission signal at
520 ± 10 nm and FRET emission signal at 620 ± 10 nm were
measured. Receptor internalization induced an increase in the
donor signal over the FRET signal, which was calculated as donor
emission signal/FRET emission signal  10,000.
2.10. Intracellular calcium measurement
Intracellular calcium release was measured as described previ-
ously (Goudet et al., 2004). Subsequently, the cells were transfected
with CB1R, Flag-SGIP1 and chimeric G-protein Gqi9 (1:2:1). After
24 h the cells were loaded with 1 mM Fluo4 AM for 1 h at 37 C
(Thermo Fisher Scientiﬁc, USA), washed and calcium release was
measured after WIN stimulation. The change in ﬂuorescence at
525 nm was measured for 60 s in 1.5 s intervals on a Multi-Mode
Microplate Reader FlexStation 3 (Molecular Devices, USA). Dose-
response curves were ﬁtted using Prism6 (GraphPad software,
USA).
2.11. Extracellular signal-regulated kinases 1/2 phosphorylation
assay
The extent of extracellular signal-regulated kinases 1/2 (ERK1/2)
phosphorylation was measured using a Phospho-ERK (Thr202/
Tyr204) Cellular Assay Kit (CellulErk®, Cisbio Bioassays, France) as
described previously (Brule et al., 2014). The cells transfected with
SNAP-CB1R and Flag-SGIP1 or pRK6 (1:2) were serum-starved
overnight, and 100 ng/ml of Pertussis toxin (Calbiochem, Czech
Republic) was added when indicated. The stimulation was per-
formed in DMEM (without FBS). The cells were kept in a incubator
for the indicated stimulation time and then lysed immediately in
50 ml of supplemented lysis buffer. Sixteen ml of the lysate was then
transferred into a 384-well small volume black plate (Greiner Bio
One, UK) in duplicates and 2 ml of anti-Phospho-ERK1/2-d2 and
Anti-ERK1/2-Eu3þCryptate antibodies were added. Fluorescence
was read at 665 nm and 620 nm using a RUBYstar Time-Resolved
Fluorescence Microplate Reader (BMG Labtechnologies, France).
Data are presented as the ratio of 665/620 nm emission  10,000.
Dose-response curves were ﬁtted using Prism6 (GraphPad soft-
ware, USA). Statistical analysis was performed using the one-way
ANOVA followed by Turkey's multiple comparison test (Prism6;
GraphPad).3. Results
3.1. Detection of SGIP1 as an interacting partner of CB1R
The yeast two-hybrid screen (Y2H) was employed to search for
interacting partners of CB1R. The sequence corresponding to the C-
terminal portion of CB1R following the 8th intracellular alpha-helix
(amino acid residues 420e473) was used as bait against a cDNA
library derived from rat forebrain. A sequence coding for the last
99 amino acids of the protein SGIP1 was detected as prey. The
interaction between the CB1R C-terminus and the SGIP1 C-termi-
nus was veriﬁed by re-transformation of both prey and bait coding
vectors into the yeast strain AH109, which was grown on selection
media lacking Ade, His, Leu, Trp and containing X-Gal. This allowed
control of transcription activation of three reporter genes (His3,
Ade2, Mel1) in parallel, reducing the incidence of false positive
results.
This approach was also used for further investigation of CB1R/
SGIP1 interaction, where serine and threonine residues were
mutated to protonated glutamic or aspartic acid respectively, in
order to mimic the potential phosphorylation that does not occur
naturally in yeast, whereas in mammals CB1R undergoes C-termi-
nal phosphorylation. None of these mutations had an effect on the
interaction of the two peptides in our assay (Fig. 1A).
3.2. SGIP1 associates with CB1R
The association between SGIP1 and CB1R was veriﬁed in vivo
using the co-immunoprecipitation technique. For immunoprecipi-
tation, sera were selected from a set of antibodies made in-house
against CB1R (not shown). To avoid co-migration of CB1R with
the antibodies on immunoblots, HEK293 cells transfected with
CB1R-GFP fusion protein were used. The selected a-CB1R05 anti-
bodies were characterized and used for immunoprecipitation.
Based on previous reports, 1% CHAPS was used for detergent sol-
ubilization. The selected a-CB1R05 serum was used to pull down
detergent soluble protein. Irrelevant rabbit antibodies were used as
a control. Next, the samples were resolved on SDS-PAGE and the
immunoblots were probed with the novel antibodies raised against
SGIP1.
The BRET approach was used to study the association of SGIP1
with CB1R in transfected HEK293 cells. SGIP1-Rluc construct con-
tained N-terminally fused Renilla luciferase (Rluc), while CB1R-YFP
was made as a C-terminal fusion protein. BRET titration curves
revealed a large and saturated increase in BRET signal between
SGIP1-Rluc and CB1R-YFP, both in the presence and absence of the
agonist. In contrast, b-arrestin1-YFP, used as a negative control,
produced only a small increase in BRET signal (Fig. 1B).
3.3. Characterization of antibodies
To detect SGIP1, antibodies were generated and characterized
using SGIP1-transfected and non-transfected (mock) HEK293 cells
prior to further studies. Immunoﬂuorescent labeling of per-
meabilized cells and immunoblotting with resolved membranes
from these cells were used (Fig. 2). Protein samples from the non-
transfected cells showed no staining with our antibodies, indicating
low background labeling of this antibody. This also suggests that
HEK293 cells do not endogenously express SGIP1, as cells trans-
fected with Flag-tagged SGIP1 were strongly stained with a pattern
suggesting membrane-associated molecules. Moreover, the N-
terminally located Flag-epitopewas also labeled in a similar pattern
(Fig. 2A). HEK293 cell (mock or Flag-SGIP1 transfected) membranes
were detected with antibodies recognizing SGIP1 and Flag-tag to
test the selectivity of the novel SGIP1 antibody. A single band with
Fig. 1. Yeast-two hybrid analysis. A) Schematic representation of CB1R e SGIP1 interaction by Y2H analysis. SGIP1 interaction with CB1R identiﬁed upon Y2H screening against the
rat forebrain cDNA library was further veriﬁed by re-transforming both prey and bait constructs into the yeast strain AH109 and growing on selective media to conﬁrm the
interaction. Further analysis of potential phosphorylation sites modiﬁcation on the interaction was performed using a series of CB1R baits in which the indicated threonine and
serine residues were mutated to the protonated states to mimic their phosphorylation. B) Co-immunoprecipitation of SGIP1 with CB1R from the CHAPS soluble fraction of rat brain
homogenates. C) BRET titration curves of HEK293 cells transiently co-transfected with constant amount of SGIP1-Rluc and increasing amount of CB1R-YFP or b-arrestin1-YFP. Cells
were stimulated with 2.5 mM WIN (S) 5 min before BRET was measured after a coelantherazine-h (5 mM) addition. NS represents non-stimulated cells.
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100 kDa) was recognized by both the SGIP1 antibodies and Flag
antibodies. Therefore, the antibodies were found to be suitable for
further studies (Fig. 2B). Similarly, mock and CB1R expressing cells
were used to characterize the a-CB1R05 antibodies used for
immunoprecipitation (Fig. 2C).
3.4. SGIP1 and CB1R co-localize in neurites
To determine whether the two molecules co-localize in the
same subcellular compartments, immunolabeling of CB1R and
SGIP1 was performed in primary neuronal cultures.
The SGIP1 protein co-localized with the axonal marker Tau1 as
well as with anti-Bassoon antibodies, which label presynapticportions of the neurites. Overlap in SGIP1 and Bassoon staining was
observed. Co-localization of SGIP1 with the dendritic marker MAP2
only partially overlapped and we concluded that SGIP1 labeling is
found on the presynaptic portions of afferent neurites. SGIP1 was
found to be present (at least partially) in neuronal compartments in
which CB1R was detected. Employing CB1R speciﬁc antibodies
together with SGIP1 detection showed an overlapping punctuated
pattern in MAP2-negative structures that corresponded to the pre-
synaptic portions observed in anti-Bassoon labeling (Fig. 3A and B).
Co-localization was quantiﬁed from ﬁve cropped regions of in-
terest (ROIs) (Fig. 3B), expressed as Pearson's (PC) and Mander's
(MC) correlation coefﬁcients mean values (Fig. 3C). Presynaptic
targeting of CB1R correlated with mean PC (xPC ¼ 0.20; SD ¼ 0.06)
and MC (xMC ¼ 0.49; SD ¼ 0.03) values obtained for CB1/MAP2
Fig. 2. Characterization of anti-SGIP1 and anti-CB1 antibodies. A) HEK293 cells were transfected with pRK6 (mock) or Flag-SGIP1, ﬁxed, permeabilized and stained with anti-
SGIP1 (SGIP1) and anti-Flag (Flag) antibodies as indicated. Images are Maximum Intensity projections of 5 stacks (z ¼ 0.25 mm). Scale bar ¼ 10 mm. B) Characterization of the anti-
SGIP antibody by Western blot. HEK293 cells were transfected with Flag-SGIP1 or pRK6 (mock). Cell lysates were separated by SDS-PAGE and then subjected to Western blotting.
Membranes were stained either with anti-SGIP1 (SGIP1), anti-Flag (Flag) or anti-Actin (actin) antibodies as indicated. C) Anti-CB1R antibody characterization. Transfected
HEK293 cells with CB1R coding expression vector and mock cells were resolved on SDS-PAGE and stained using antibodies.
Fig. 3. Co-localization of SGIP1 with compartment-speciﬁc neuronal markers and CB1R in cultured cortical neurons A) Speciﬁc neuronal compartments were labeled by
dendritic (MAP2), axonal (Tau1), and presynaptic terminal (Bassoon) markers in cultured cortical neurons. The localization of the markers, SGIP1 and CB1R is shown. Scale
bar ¼ 20 mm. B) Cropped images from the yellow ROIs in A. Speciﬁc neuronal structures are indicated with yellow arrows, where the punctuated signal of SGIP1 and CB1R was
detected. C) Dual-channel cropped images representing the overlap of two labeled proteins. Endogenous SGIP is always represented by intensities in the red channel, the green
channel expresses endogenous CB1R signal and the grey channel corresponds to MAP2 labelling. Scale bar ¼ 1 mm. D) Statistical analysis of overlapping pixel intensities in dual-
channel images of CB1R and SGIP1 or both proteins separately with MAP2 from regions corresponding to detail cropped images on left side were performed and expressed as
Pearson's (PC) and Mander's (MC) coefﬁcient mean values (C) shown in the graphs.
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by MAP2 contrasted with the punctuated ﬂuorescence observed
with CB1R and SGIP1 that share a similar ﬂuorescence pattern
(Fig. 3B). SGIP1 is not strictly targeted to presynaptic portions due
to higher PC and MC mean values (xPC ¼ 0.48, SD ¼ 0.07;
xMC ¼ 0.71; SD ¼ 0.05) obtained for SGIP/MAP2. Nevertheless, the
mean value of CB1R/SGIP1 (xMC ¼ 0.75; SD ¼ 0.01) indicates
stronger co-localization of CB1 with SGIP1 than obtained for SGIP/
MAP2 (xMC ¼ 0.71; SD ¼ 0.05) and SGIP1/CB1R (xMC ¼ 0.69,
SD ¼ 0.05).
3.5. SGIP1 impedes endocytosis of activated CB1R
The TR-FRET based method was used to investigate whether
SGIP1 interaction with CB1R inﬂuences internalization of the acti-
vated receptor, as reported for other cargoes (Uezu et al., 2007).
With this method, the ﬂuorescence signal of benzyl guanidine-
cryptate-labeled N-terminally tagged SNAP-CB1R at the cell sur-
face is quenched by the ﬂuorescein dye present in the medium at a
high concentration (24 mM). An increase in donor signal is related to
internalization of the receptor, as the signal is not quenched by
extracellular ﬂuorescein. Signiﬁcant CB1R internalization after both
5 mM 2-AG and 2.5 mMWIN stimulation in HEK293 cells expressing
CB1R alone was observed. Both agonists initiated prompt and
massive internalization of comparable pace and extent. Interest-
ingly, when CB1R was co-expressed with SGIP1, agonist induced
endocytosis was signiﬁcantly reduced (percentage of maximal
CB1R internalization after WIN stimulation ± SEM, where mean
internalization of CB1R alone was set to 100 %: CB1R_2-
AG ¼ 100 ± 3.4%; CB1R þ SGIP1_2-AG ¼ 29.1 ± 0.12% and
CB1R_WIN ¼ 100 ± 1.6%; CB1R þ SGIP1_WIN ¼ 30.2 ± 0.37%, n¼ 3,
*P ˂ 0.0001) (Fig. 4A).
The dominant negative dynamin mutant K44A (DynK44A) has
previously been shown to block clathrin-coated pit (CCP) mediated
endocytosis. DynK44A was used to elucidate the mechanism of
SGIP1 interference with CB1R endocytosis. The inhibitory effect of
DynK44A on WIN mediated CB1R internalization was greater
(CB1R þ DynK44A ¼ 9.2 ± 1.3%, n ¼ 3) than when SGIP1 was co-
transfected (see above).
SGIP1 also affected CB1R internalization without agonist addi-
tion. Such internalizationwas quantitatively lower that one elicited
by high doses of agonists in the absence of SGIP1, but was also
almost diminished by the presence of SGIP1. As expected, the in-
verse agonist 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-
N-4-morpholinyl-1H-pyrazole-3-carboxamide (AM281) did inter-
fere with the internalization of CB1R observed without agonist
treatment. However, it had no apparent effect on internalization of
CB1R expressed in tandem with SGIP1, as the internalization was
prevented by the presence of SGIP1 (Fig. 4B). As this assaymeasures
the ﬂuorescence signal of the intracellular pool of receptors, the
different ﬂuorescence proﬁles measured in cells with and without
SGIP1 show that the internal pool of receptors is smaller in the
presence of SGIP1. Conversely, surface expression levels in non-
stimulated cells were comparable in cells expressing CB1R alone,
in tandem with SGIP1, or with DynK44A (Fig. 4C).
The results of agonist driven internalization were conﬁrmed
using live-cell immunoﬂuorescence labeling of the HEK293 cells
transfected with CB1R with or without SGIP1 (Fig. 4D). Prior to
activation, anti-CB1R antibody was used for staining cell surface
exposed receptors. After stimulation with WIN or DMSO (30 mi-
nutes), cells were treatedwith an excessive amount of two different
secondary antibodies. Primarily applied secondary antibody
labeled the extracellular CB1R epitopes. After permeabilization,
another secondary antibody with a different ﬂuorophore recog-
nized the internalized pool of CB1R. CB1R internalization wascalculated as the ratio between the internalized pool and cell sur-
face CB1R staining. Following WIN stimulation, CB1R internaliza-
tionwas signiﬁcantly decreased in the presence of SGIP1 compared
to CB1R alone (FIR ± SEM values for CB1R ¼ 2.139 ± 0.18;
CB1R þ SGIP1 ¼ 0.642 ± 0.24; n ¼ 8; *P ˂ 0.0001).
3.6. b-arrestin2 association with activated CB1R is enhanced by
SGIP1
b-arrestins are adaptor molecules that interact with desensi-
tized GPCRs, endocytic machinery molecules and speciﬁc signaling
cascademolecules. The BRET based assay was used tomeasure cells
co-expressing b-arrestin1-Rluc or b-arrestin2-Rluc and CB1R-YFP,
where an increase of BRET signal reﬂected the recruitment of b-
arrestin by the receptor upon either 5 mM 2-AG or 2.5 mM WIN
treatment. No associations elicited by either agonist between CB1R
and b-arrestin1, with or without SGIP1, were observed.
In cells expressing CB1R without SGIP1, the b-arrestin2-Rluc/
CB1R-YFP signal reached its maximum 5 min after the application
of either of the two agonists and decreased to basal levels within an
hour, although the effect mediated by 2-AG was much lower than
that of WIN (Fig. 5). In cells co-expressing SGIP1, the dynamics of
the association between CB1R and b-arrestin2 after WIN stimula-
tion was reminiscent of that without SGIP1, with culmination in
5 min, but BRET efﬁciency reached considerably higher values and
persisted for an extended time. Therefore SGIP1 profoundly affects
the interaction between CB1R and b-arrestin2 (net mBRET
values ± SEM in 5 minutes: CB1R ¼ 36.9 ± 2.8;
CB1Rþ SGIP1¼ 54 ± 0.9; n¼ 3). The effect was even higher in cells
co-transfectedwith CB1R and DynK44A (net mBRET value ± SEM in
5 minutes: CB1R þ DynK44A ¼ 64 ± 1.2; n ¼ 3).
3.7. SGIP1 does not interfere with CB1R mediated G-protein
activation
To test whether CB1R signaling via Gi/Go activation is affected
by SGIP1, a G-alpha BRET-based sensor was used to monitor
conformational changes between alpha and gamma G-protein
subunits. Both Gi/Go activations mediated by CB1R stimulation
were tested with increasing concentrations of WIN. In both cases,
activation of the receptor was followed by a prompt decrease in
BRET signal efﬁciency, reﬂecting activation of the G-proteins
(Fig. 6A). These changes were similar when measured in cells
transfected with CB1R alone or together with SGIP1 for the tested
G-subunits (logEC50 ± SEM for Gi activation: CB1R¼7.5 ± 0.1 nM;
CB1R þ SGIP1 ¼ 7.5 ± 0.1 nM; Go activation:
CB1R ¼ 7.4 ± 0.1 nM; CB1R þ SGIP1 ¼ 7.5 ± 0.1 nM, n ¼ 3).
The measurement of intracellular calcium release was assessed
using co-transfection with the chimeric G-protein Gqi9. Intracel-
lular calcium was measured as an increase in ﬂuorescence in
transiently transfected HEK293 cells loaded with Fluo-4 dye. No
signiﬁcant differences in CB1R-Gqi9 mediated calcium mobility
with or without SGIP1 were observed (logEC50 ± SEM values: CB1R
WIN¼6.7 ± 0.1 nM; CB1Rþ SGIP12-AG¼6.7 ± 0.1 nM; CB1R 2-
AG ¼ 6.2 ± 0.3 nM; CB1R þ SGIP1 2-AG ¼ 6 ± 0.3 nM) upon
either 2-AG or WIN mediated activation. These results suggest that
acute G-protein signaling of CB1R elicited by a single-dose of either
agonist is not markedly inﬂuenced by SGIP1 (Fig 6B).
3.8. SGIP1 alters ERK1/2 signaling of CB1R
The role of SGIP1 on ERK1/2 signaling following CB1R activation
was also investigated. In HEK293 cells transiently expressing CB1R
ERK1/2 phosphorylation was induced by adding 5 mM 2-AG
(Fig. 7A). The time course of ERK1/2 phosphorylation upon CB1R
Fig. 4. SGIP1 interferes with internalization of activated CB1R. A) HEK293 cells were transiently transfected with SNAP tagged CB1R together with DynK44, Flag-SGIP1 or an
empty vector respectively. The level of CB1R internalization was measured after 5 mM 2-AG or 2.5 mM WIN stimulation at indicated times. The relative level of receptor inter-
nalization is calculated as the percentage ratio of the maximal internalization measured for CB1R alone after 5 mM 2-AG or 2.5 mMWIN stimulation respectively. The data represent
means ± SEM of quadruplicates from a single experiment. Two further experiments produced similar results. B) The extent of CB1R internalization was also measured without
agonist addition as well as with 7 mM inverse agonist AM-281 in cells transfected, as above. C) CB1R expression level determination. The SNAP-CB1R expression vector was
transiently transfected alone or in tandemwith Flag-SGIP1 or DynK44A into the HEK293 cells. After 24 h, the SNAP tag was labeled with benzyl guanine carrying europium cryptate
(BG-K) and its emission signal reﬂecting the amount of surface CB1R was measured at 620 nm on an Inﬁnite F500 microplate reader. D) HEK293 cells were transfected with CB1R or
CB1R þ SGIP1 and stimulated with 0.5 mMWIN (or DMSO as a control) for 30 minutes. Images shown are Z-projections of maximal intensity. The red color represents surface CB1R
while green represents internalized CB1R. Scale Bar 10 mm. E) Graph showing the ﬂuorescence internalization ratio (FIR), calculated as the ratio between the internalized and cell
surface CB1R. Each value represents mean ± SEM (n ¼ 8). Signiﬁcant difference was determined using an unpaired t-test, P ˂ 0.0001.
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Fig. 5. b-arrestin2 association with activated CB1R is enhanced by SGIP1. HEK293 cells were transiently transfected with a particular b-arrestin-Rluc variant together with CB1R-
YFP and with Flag-SGIP1 or DynK44A. Cells were stimulated with 5 mM (pannel A) 2-AG or 2.5 mM WIN (panel B) for the indicated time, and after the addition of 5 mM
coelantherazine-h the BRET signal was measured on a Mithras LB940 plate reader. Data represent the mean ± SEM from three independent experiments performed in triplicate.
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observed at around 5 min after agonist application. The maximal
response and overall levels of ERK1/2 phosphorylation for the
tested agonists were noticeably lower in cells co-expressing SGIP1
and the CB1R. We performed statistical analysis using the one-way
ANOVA followed by Turkey's multiple comparison test for the re-
sponses in cells treated with 2-AG at peak response. There was a
signiﬁcant increase (P < 0.0001, n ¼ 7) in ERK1/2 phosphorylation
when CB1 was expressed alone compared to vehicle (DMSO)
stimulation. There was also a signiﬁcant difference (P < 0.0001,
n ¼ 7) between the effect mediated by 2-AG on CB1R when
expressed alone or in tandem with SGIP1.
Treatment of 2.5 mM WIN (Fig. 7B, left) led to greater responses
compared to 2-AG. SGIP1 also led to depression of the responses.
Co-expression with DynK44A resulted in decreased ERK1/2
signaling similar to that observed with SGIP1, however the signal
was more delayed and persisted for a longer period with DynK44A.
Pre-treatment of the cells with Pertussis toxin (PTX) abolished the
activated-CB1R-induced ERK1/2 phosphorylation in cells express-
ing CB1R alone and in cells co-expressing CB1R with SGIP1 as well
(Fig. 7B, right).
The dose-response experiment measured after 5 min of 2.5 mM
WIN stimulation (Fig. 7C) conﬁrmed lower ERK1/2 phosphorylation
levels mediated by stimulated CB1R upon co-expression with
SGIP1, while the EC50 values remained comparable (logEC50 ± SEM
values: CB1R ¼ 6.9 ± 0.05 nM; CB1R þ SGIP1 ¼ 6.9 ± 0.05 nM;
CB1R þ DynK44A ¼ 6.8 ± 0.08 nM, n ¼ 3).4. Discussion
We report the functional consequences of association between
CB1R and SGIP1. The interaction was detected using Y2H (Fig. 1A)
and conﬁrmed by co-precipitation from detergent soluble of brain
and also using the BRET approach (Fig. 1C). The proximity of SGIP1
and CB1R detected by BRET was not inﬂuenced by the presence or
absence of the CB1R agonist WIN. As a control molecule, we chose
b-arrestin1, which does not interact with non-activated CB1R. As
expected, our results show that b-arrestin1 does not interact with
SGIP1.
In rodents, SGIP1 is expressed almost exclusively in the CNS
(Trevaskis et al., 2005). The pattern of expression of mRNAs for
both, SGIP1 and CB1R, as documented in Allen's Brain Atlas, is
largely overlapping, but expression levels seem to vary in different
brain regions and cell types (http://mouse.brain-map.or, 2015; Lein
et al., 2007). Detailed study of co-localization of the two proteins in
various cell types and subcellular compartments, especially in
respect to pre-synaptic distribution, deserves investigation on
nanoscale level, as in recent elegant study on CB1R detection and its
redistribution upon chronic THC exposures (Dudok et al., 2015).
We veriﬁed the co-localization of CB1R and SGIP1 in cultured
neurons derived from prefrontal cortex. We observed strong co-
localization of SGIP1 with axonal (Tau1) and presynaptic
(Bassoon) markers. The pattern of partial co-localization with the
dendritic marker MAP2 reﬂects the distribution of SGIP1 in pre-
synaptic terminals (Fig. 3). Thus, SGIP1 is preferentially targeted to
Fig. 6. SGIP1 does not signiﬁcantly change CB1R mediated G-protein activation. A) Dose response curves of Ga subunit dissociation from the G-protein complex after CB1R
stimulation with increasing concentrations of WIN. HEK293 cells were simultaneously transiently co-transfected with Gai1-Rluc8 or GaoA-Rluc8, Gb2-Flag, Gg2-VENUS, CB1R, and
SGIP1 or an empty vector. Twenty-four hours after transfection, 5 mM coelantherazine-h was added, cells were stimulated with increasing concentrations of WIN and the decrease in
BRET signal due to dissociation of the Ga subunit from the G-protein complex was measured. B) CB1R mediated intracellular calcium mobilization in response to stimulation with
various concentrations of 2-AG or WIN. HEK293 cells were transiently transfected with CB1R, chimeric G-protein Gqi9 and Flag-SGIP1 or an empty vector. Cells were loaded with
Fluo-4 and calcium release was measured. Data represent the mean ± SEM of three independent experiments performed in triplicate.
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lished ﬁndings identifying SGIP1 as a highly abundant presynaptic
protein (Wilhelm et al., 2014).
It has been shown previously that SGIP1 decreases the rate of
endocytosis of receptors that do not belong to the GPCR family
(Uezu et al., 2007). We discovered that SGIP1 confers cell surface
stability of the activated CB1R in co-transfected HEK293 cells and
also blocks internalization of the receptor that occurs without any
added agonists (Fig. 4). This sheds light on the possible machinery
and may explain discrepancies reported in heterologous systems
where signiﬁcant CB1R internalization was observed and obser-
vations in neuronal cell bodies where limited internalization of
CB1R located in presynaptic regions was observed (Straiker et al.,
2012; Hsieh et al., 1999; Leterrier et al., 2006; Jin et al., 1999).
Recent study on chronic THC treatment revealed, that diminishing
of CB1R is cell-type speciﬁc. Thus, among others, it remains to be
speciﬁed on nanoscale level, whether SGIP1 expression differs, for
example, between GABAergic and glutamatergic synapses in hip-
pocampus (Dudok et al., 2015). We did follow only acute internal-
ization patterns of CB1R with and without SGIP1. Further studies
using transgenic animals might resolve the in vivo situation
following chronic THC treatment in respect with SGIP1 effect on
CB1R signaling in distinct cell populations.
WIN-mediated activation of CB1R was shown to cause b-
arrestin2, but not b-arrestin1 recruitment to the activated receptors(Daigle et al., 2008). SGIP1 enhanced association with b-arrestin2
upon activation with WIN or the endocannabinoid 2-AG. This
ﬁnding excluded the possibility that decreased rates of activated
CB1R internalization may be caused by SGIP1 competition with b-
arrestins binding to the phosphorylated C-terminus of CB1R. No
detectable interaction of b-arrestin1 with or without SGIP1 upon
activation with WIN or 2-AG was detected (Fig. 5). Phosphorylated
states of certain threonine and serine residues of the C-terminal
region of CB1R precede the recruitment of b-arrestin2 to CB1R. In
our Y2H experiments, we showed that mutation of these residues
(and others) which mimic their phosphorylated states do not in-
ﬂuence the interaction between SGIP1 and CB1R. (Fig. 1). Alteration
of CB1R endocytosis by DynK44A changed the association with b-
arrestin2 to a larger extent than SGIP1 (Fig. 5B). DynK44A blocks
endocytosis at the latest steps of membrane invagination, prior to
the scission of CCP, just before the formation of the vesicle and
entrance into the cytoplasm, while SGIP1 probably interferes with
the initial stages of CME.
A possible explanation for the SGIP1 mediated enhancement of
b-arrestin2 association with CB1R is a lack of CB1R/b-arrestin2
complex sequestration that would occur upon receptor internali-
zation and post-endocytic processing (see proposed model in
Fig. 8) (Shukla et al., 2011; Luttrell and Gesty-Palmer, 2010; Shenoy
et al., 2009; Tohgo et al., 2003; Pierce et al., 2000). Another possi-
bility is that the recruitment of b-arrestin2 to the activated and
Fig. 7. CB1R mediated ERK1/2 signaling is hindered by SGIP1. HEK293 cells were transiently transfected with CB1R and co-transfected with either DynK44A or Flag-SGIP1 or an
empty vector. The kinetics of CB1R mediated ERK1/2 phosphorylation were measured after addition of 5 mM 2-AG (panel A). Evaluation was performed after 5 minutes of stim-
ulation. There was a signiﬁcant difference between CB1R alone stimulated with 2-AG or DMSO (P < 0.0001, n ¼ 7) and between the 2-AG effect on CB1R alone or in tandem with
SGIP1 (P < 0.0001, n ¼ 7). B) ERK1/2 activation using synthetic ligand WIN without (left), or after PTX pretreatment (right) C) Dose response curves of ERK 1/2 phosphorylation
mediated via WIN stimulated CB1R alone or in tandemwith SGIP1 or DynK44A. Data represent the mean ± SEM of three independent experiments performed in triplicate with the
exception of the 2-AG stimulation for 0e30 minutes where seven independent experiments in triplicate were performed.
A. Hajkova et al. / Neuropharmacology 107 (2016) 201e214 211phosphorylated CB1R results in a different conformation of the
arrestin molecule in the presence or absence of SGIP1 (Shukla et al.,
2008).
SGIP1, together with the membrane-curvature-associated FCH
domain only proteins FCHo1 and FCHo2 (FCHo1/2), belongs to the
muniscin family that are involved in CME. While FCHo1/2 proteins
have been shown to be involved in sustaining or promoting the
initial phases of CME (Cocucci et al., 2012; Henne et al., 2010; Trauband Wendland, 2010), SGIP1 was shown to prevent the internali-
zation of several cargoes (Uezu et al., 2007). The overall structure of
the muniscins consists of the N-terminal lipid-binding domain,
followed by protein-protein interaction mediating modules: AP2
binding site, a proline-rich region that occupies the central part of
the polypeptide and the C-terminal part known as medium m-
domain of adaptor proteins (Henne et al., 2010; Hollopeter et al.,
2014). These domains participate in the formation of intracellular
Fig. 8. Proposed model of SGIP1 effect on CB1R internalization and signaling. A) Transfected cells without SGIP1. Upon CB1R agonist induced signaling through Gi/o, the re-
ceptor associates with b-arrestin and is readily internalized, which allows massive ERK1/2 activation. B) In cells expressing SGIP1, internalization is prevented at the early stages.
Therefore, G-protein signaling is unaltered. However, the extent of CB1R signaling via the ERK1/2 pathway is decreased, as SGIP1 competes with FCHo1/2 proteins required for the
initial stages of clathrin-coated pit formation. Thus, the internalization of CB1R is abrupt at the early stage, when the pits are in the initial phases of growth, or even before this
event. SGIP1 prevents ERK1/2 signaling of the receptor-b-arrestin complex that would occur during further steps of internalization. Conversely, b-arrestin association with CB1R is
enhanced as their dissociation, which normally occurs in internalized endocytic compartments, does not occur. C) Blockade of endocytosis in later stages. DynK44A hinders CB1R
internalization at the stage of endocytosis prior to scission of the clathrin coated pits. We assume that at this stage, the effect on signaling via ERK1/2 already proceeds and is
extended, compared to the situation with SGIP1 or the receptor alone that internalizes, which leads to b-arrestin dissociation. This corresponds to the ﬁnding that DynK44A elevates
CB1R- b-arrestin association.
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on SGIP1 adjacent to the membrane interacting domain was
recently identiﬁed for the clathrin adaptor protein complex AP2. Its
interactionwith the corresponding motif on FCHo1/2 results in AP2
activation (Hollopeter et al., 2014). Thus, another part of the SGIP1
molecule has to overcome AP2 activation. Such a motif may be the
97 amino acid residue N-terminal region, which was shown to
interact with plasma membrane lipids.
We hypothesize that SGIP1 interferes with endocytosis by
competition with FCHo1/2 proteins. FCHo1/2 have the N-terminal
portion folded to form F-Bar domains that are responsible for
plasma membrane shaping in CME pit formation (Henne et al.,
2007), while the MP region of SGIP1 has no sequence similarity
to these F-Bar structures. The most appealing hypothesis is that the
MP region of SGIP1 interacts with the membrane in a different
manner than FCHo1/2.
The association between SGIP1 and CB1R, as well as the
resulting interference with the internalization of the activated re-
ceptor, has speciﬁc consequences on CB1R signaling. The activation
of Gai1 and GaoA proteins was measured as a change in BRET ef-
ﬁciency between Ga and Gg subunits and dose response mea-
surements using the Gaqi9 fusion protein in a Caþþmobility assay.
The results showed no signiﬁcant difference in the activation of the
G-proteins by the CB1 receptor in the presence or absence of SGIP1
(Fig. 6). Conversely, we found that CB1R elicited ERK1/2 phos-
phorylation was profoundly altered by SGIP1. The extent of ERK1/2
phosphorylation was reduced substantially by SGIP1, while the
kinetic proﬁle of ERK1/2 activationmediated by CB1R upon 2-AG or
WIN application was comparable in the presence and absence of
SGIP1 (Fig. 7).
ERK1/2 activation with or without SGIP1 was abolished in our
experiments by PTX treatment. PTX did abolish ERK1/2 signaling
elicited by CP55940 ((1R,3R,4R)-3-[2-hydroxy-4-(1,1-
dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol),but was not abolished when allosteric modulator ORG27569 (5-
chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-
phenyl)ethyl]amide) was used in previous report (Ahn et al., 2012).
This suggests that ERK1/2 signaling is dependent on Gai-protein
activation, that would elicit corresponding downstream signaling
using WIN or CP55940, but distinct downstream signaling by G-
protein Coupled Receptors Kinases activation takes place in pres-
ence of ORG27569 (Ahn et al., 2013). These ﬁndings parallel data
from studies including situation in neuronal cells, where WIN
stimulated CB1R mediated PTX sensitive ERK1/2 phosphorylation
(Baillie et al., 2013; Dalton and Howlett, 2012).
DynK44A was also employed in the functional tests. In the
presence of DynK44A, CB1R mediated ERK1/2 activation reached
the same maximal levels as it did with SGIP1, but for a longer
duration suggesting internalization and signaling during post-
endocytic sorting of the receptor plays an important role in ERK1/
2 signalization (see proposed model in Fig. 8) (Daaka et al., 1998).
Signaling bias was recognized for GPCR ligands that are likely to
promote or stabilize speciﬁc conformations of their heptahelical
domains. Novel molecules that adjust GPCR signaling by mecha-
nisms other than the ligand-dependent stabilization of speciﬁc
conformations were also developed; e.g., peptides derived from
sequences of the intracellular loops connecting transmembrane
alpha-helices (Quoyer et al., 2013). Also, single-domain antibodies
(nanobodies), which are directed against intracellular regions of
receptors, stabilized it in its active or inactive state (Staus et al.,
2014). The intrinsic modulator of CB1R signaling, pregnenolone,
acting as an allosteric biased signaling modulator, was shown to act
as an ERK1/2-pathway speciﬁc inhibitor, leaving CB1R G-protein
coupling unmodiﬁed (Wilhelm et al., 2014). Interestingly, SGIP1
elicits a similar effect on CB1R signaling as pregnenolone, however,
the mechanism of this bias is likely different. Pregnenolone was
proposed to interact with CB1R in a region constituted by a helices
(Vallee et al., 2014), while we identiﬁed the SGIP1 interaction site
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SGIP1 overexpression in vivo is associated with energy misbal-
ance and obesity in animals (Trevaskis et al., 2005) and genetic
variations within the SGIP1 gene are associated with energy bal-
ance disturbances in humans (Cummings et al., 2012). If the CB1R
signaling pathway(s) affected in obese individuals could be phar-
macologically inﬂuenced separately from the pathways involved in
mental safeguarding well-being, then safer andmore effective anti-
obesity drugs could be developed. Only after the signaling pathway
of CB1R in the obesity phenotype has been elucidated can speciﬁc
antagonists, or partial agonists be developed while minimizing
adverse effects such as those reported for Rimonabant. This anti-
obesity drug was withdrawn from the market after evaluation of
the risk-beneﬁt ratio due to its severe psychiatric side effects.
Pharmacological characterization of CB1R ligands on CB1R
signaling has thus far been performed mostly in heterologous
systems, in the absence of SGIP1. Therefore, further investigation
into the signaling properties of the receptor and the effects of the
molecular components of the signalosome on its properties are
needed.
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